{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:47:42Z","timestamp":1793029662546,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Capivasertib is recommended, plus fulvestrant, for hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with\n                      <jats:italic>PIK3CA<\/jats:italic>\n                      \/\n                      <jats:italic>AKT1<\/jats:italic>\n                      \/\n                      <jats:italic>PTEN<\/jats:italic>\n                      alterations and is under development for further breast and prostate cancer indications. Pharmacokinetics in Western and Japanese patients have been previously characterized. We conducted a Phase I trial assessing the pharmacokinetics and safety of capivasertib, alone or plus paclitaxel, in Chinese patients with advanced solid tumors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this open-label, fixed-sequence Phase I trial, Chinese patients with advanced solid tumors refractory or resistant to standard therapy received capivasertib alone (Part A) and then plus paclitaxel (Part B). The primary endpoint comprised capivasertib pharmacokinetics after a single dose (480 mg), or multiple doses given alone (480 mg twice daily [4 days on, 3 days off]) or plus paclitaxel (capivasertib 400 mg twice daily [4\u00a0days on, 3 days off], paclitaxel 80 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      once weekly; both 3 weeks on, 1 week off). Safety was a secondary endpoint. Investigator-assessed best objective response was an exploratory endpoint.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 16 patients (median age 55.5 years, median weight 58.9\u00a0kg, 81.3% breast primary tumor location) received capivasertib alone in Part A and then capivasertib plus paclitaxel in Part B. The median time to maximum concentration, the geometric mean maximum plasma concentration, and the geometric mean area under the curve from time 0 to the last quantifiable concentration of capivasertib were: after a single dose (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916): 1.0\u00a0h, 1465 ng\/mL, and 7243\u00a0h\u00d7ng\/mL; after multiple doses (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915): 0.9\u00a0h, 2535 ng\/mL, and 12,080\u00a0h\u00d7ng\/mL; after multiple doses plus paclitaxel (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098): 1.9\u00a0h, 2467 ng\/mL, and 12,830\u00a0h\u00d7ng\/mL, respectively. After a single dose, the geometric mean terminal elimination half-life was 9.7\u00a0h. Hyperglycemia, diarrhea, and rash were the most common adverse events (reported for all patients). Most adverse events were Grade 1\u20132. Four (25.0%) patients achieved confirmed partial response and four (25.0%) stable disease as best objective response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Consistent with previous findings, capivasertib was absorbed rapidly and eliminated with a half-life of approximately 10 h. The manageable safety profile and preliminary antitumor activity support further investigation of capivasertib-containing combinations in Chinese patients with advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The trial was registered at ClinicalTrials.gov with identifier no. NCT04742036. Date of registration: February 4, 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-14982-4","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T10:01:05Z","timestamp":1760436065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors"],"prefix":"10.1186","volume":"25","author":[{"given":"Jian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Cullberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"1","key":"14982_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","volume":"18","author":"J Yang","year":"2019","unstructured":"Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26.","journal-title":"Mol Cancer"},{"issue":"4","key":"14982_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","volume":"170","author":"DA Fruman","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605\u201335.","journal-title":"Cell"},{"key":"14982_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","volume":"67","author":"IA Mayer","year":"2016","unstructured":"Mayer IA, Arteaga CL. The PI3K\/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67:11\u201328.","journal-title":"Annu Rev Med"},{"issue":"8","key":"14982_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"14982_CR5","doi-asserted-by":"publisher","first-page":"e95219","DOI":"10.1371\/journal.pone.0095219","volume":"9","author":"A Ocana","year":"2014","unstructured":"Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, et al. Activation of the PI3K\/mTOR\/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS ONE. 2014;9(4):e95219.","journal-title":"PLoS ONE"},{"key":"14982_CR6","doi-asserted-by":"publisher","first-page":"628690","DOI":"10.3389\/fphar.2021.628690","volume":"12","author":"C Dong","year":"2021","unstructured":"Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol. 2021;12:628690.","journal-title":"Front Pharmacol"},{"issue":"4","key":"14982_CR7","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","volume":"11","author":"BR Davies","year":"2012","unstructured":"Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11(4):873\u201387.","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"14982_CR8","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058\u201370.","journal-title":"N Engl J Med"},{"key":"14982_CR9","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1038\/s41467-025-59210-6","volume":"16","author":"QZ Xichun Hu","year":"2025","unstructured":"Hu X, Zhang Q, Sun T, Xiong H, Li W, Teng Y, et al. Capivasertib plus fulvestrant in patients with HR-positive\/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort. Nat Commun. 2025;16(1):4324.","journal-title":"Nat Commun"},{"issue":"12","key":"14982_CR10","first-page":"1092","volume":"33","author":"The Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association","year":"2023","unstructured":"The Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association. Guidelines for breast cancer diagnosis and treatment by China Anti-cancer association (2024 edition). China Oncol. 2023;33(12):1092\u2013187.","journal-title":"China Oncol"},{"key":"14982_CR11","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Breast Cancer Version 6.2024. \u00a9 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed November 12, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"9 Suppl","key":"14982_CR12","first-page":"PO2","volume":"84","author":"H Rugo","year":"2024","unstructured":"Rugo H, Pistilli B, Collins J, D\u2019Cruz C, Gresty C, Sommavilla R, et al. Abstract PO2-19-10: CAPItello-292 phase 3: an open-label, randomized study of capivasertib, fulvestrant, and investigator\u2019s choice of CDK4\/6 inhibitor (palbociclib or ribociclib) in HR+\/HER2- advanced breast cancer. Cancer Res. 2024;84(9 Suppl):PO2-19-0.","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"14982_CR13","doi-asserted-by":"publisher","first-page":"S1212","DOI":"10.1016\/j.annonc.2024.08.2257","volume":"35","author":"P Schmid","year":"2024","unstructured":"Schmid P, McArthur HL, Cort\u00e9s J, Xu B, Cardoso F, Casalnuovo ML, et al. LBA19 Capivasertib (C)\u2009+\u2009paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): the CAPItello-290 phase III trial. Ann Oncol. 2024;35(Suppl 2):S1212\u20133.","journal-title":"Ann Oncol"},{"issue":"6 Suppl","key":"14982_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS178","volume":"39","author":"K Fizazi","year":"2021","unstructured":"Fizazi K, George DJ, Santis MD, Clarke N, Fay AP, Uemura H, et al. A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281). J Clin Oncol. 2021;39(6 Suppl):TPS178.","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"14982_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS287","volume":"41","author":"SJ Crabb","year":"2023","unstructured":"Crabb SJ, Ye DW, Uemura H, Morris T, Gresty C, Logan J, et al. CAPItello-280: a phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer. J Clin Oncol. 2023;41(6 Suppl):TPS287.","journal-title":"J Clin Oncol"},{"issue":"9","key":"14982_CR16","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-17-2260","volume":"24","author":"U Banerji","year":"2018","unstructured":"Banerji U, Dean EJ, P\u00e9rez-Fidalgo JA, Batist G, Bedard PL, You B, et al. A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers. Clin Cancer Res. 2018;24(9):2050\u20139.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"14982_CR17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/annonc\/mdz086","volume":"30","author":"NC Turner","year":"2019","unstructured":"Turner NC, Alarc\u00f3n E, Armstrong AC, Philco M, L\u00f3pez Chuken YA, Sablin MP, et al. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann Oncol. 2019;30(5):774\u201380.","journal-title":"Ann Oncol"},{"key":"14982_CR18","unstructured":"Jones R, Howell S, Rugman P, Casbard A, Bongard E. FAKTION; phase 1b\/2 randomised placebo controlled trial of fulvestrant +\/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a 3rd generation aromatase inhibitor. Presented at NCRI Cancer Conference, November 6\u20139, 2016, Liverpool, UK."},{"issue":"2","key":"14982_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.clgc.2022.11.017","volume":"21","author":"N Shore","year":"2023","unstructured":"Shore N, Mellado B, Shah S, Hauke R, Costin D, Adra N, et al. A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2023;21(2):278\u201385.","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"14982_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10637-017-0433-4","volume":"35","author":"SJ Crabb","year":"2017","unstructured":"Crabb SJ, Birtle AJ, Martin K, Downs N, Ratcliffe I, Maishman T, et al. ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2017;35(5):599\u2013607.","journal-title":"Invest New Drugs"},{"issue":"5","key":"14982_CR21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00280-018-3558-z","volume":"81","author":"E Dean","year":"2018","unstructured":"Dean E, Banerji U, Schellens JHM, Krebs MG, Jimenez B, van Brummelen E, et al. A phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK. Cancer Chemother Pharmacol. 2018;81(5):873\u201383.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"14982_CR22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00280-016-2987-9","volume":"77","author":"K Tamura","year":"2016","unstructured":"Tamura K, Hashimoto J, Tanabe Y, Kodaira M, Yonemori K, Seto T, et al. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77(4):787\u201395.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"14982_CR23","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1111\/bcp.15831","volume":"89","author":"C Miller","year":"2023","unstructured":"Miller C, Sommavilla R, Murphy D, Morris T, Khatun M, Cullberg M. The effect of food and acid-reducing agents on the pharmacokinetic profile of capivasertib: results from a randomised, cross-over study. Br J Clin Pharmacol. 2023;89(11):3330\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"14982_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00280-024-04667-3","volume":"94","author":"C Miller","year":"2024","unstructured":"Miller C, Sommavilla R, O\u2019Bryant CL, Barve M, Dowlati A, Luke JJ, et al. Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2024;94(2):223\u201335.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"14982_CR25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1124\/dmd.124.001636","volume":"52","author":"C Miller","year":"2024","unstructured":"Miller C, Wild M, Zhang Z, Sommavilla R, Shanahan D, Bailey C, et al. A phase I study to determine the absolute bioavailability and absorption, distribution, metabolism, and excretion of capivasertib in healthy male participants. Drug Metab Dispos. 2024;52(9):939\u201348.","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"14982_CR26","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/cpdd.1307","volume":"12","author":"C Miller","year":"2023","unstructured":"Miller C, Sommavilla R, Barry ST, Eberlein C, Morris T, Wadsworth I, et al. Pharmacokinetics of the Akt serine\/threonine protein kinase inhibitor, capivasertib, administered to healthy volunteers in the presence and absence of the CYP3A4 inhibitor itraconazole. Clin Pharmacol Drug Dev. 2023;12(9):856\u201362.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"14982_CR27","unstructured":"AstraZeneca Pharmaceuticals LP. Highlights of prescribing information. TRUQAP\u2122 (capivasertib) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/218197s000lbl.pdf"},{"issue":"8","key":"14982_CR28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40262-024-01407-x","volume":"63","author":"C Fernandez-Teruel","year":"2024","unstructured":"Fernandez-Teruel C, Cullberg M, Eberlein C, Barry ST, Zhou D. Population pharmacokinetics of capivasertib in patients with advanced or metastatic solid tumours. Clin Pharmacokinet. 2024;63(8):1191\u2013204.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"14982_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.19.00368","volume":"38","author":"P Schmid","year":"2020","unstructured":"Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol. 2020;38(5):423\u201333.","journal-title":"J Clin Oncol"},{"issue":"7","key":"14982_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70286","volume":"18","author":"C Fernandez Teruel","year":"2025","unstructured":"Fernandez Teruel C, Cullberg M, Gonz\u00e1lez-Garc\u00eda I, Schiavon G, Zhang L, Zhou D. Population pharmacokinetics and exposure-response analyses for capivasertib in combination with fulvestrant in patients with breast cancer. Clin Transl Sci. 2025;18(7):e70286.","journal-title":"Clin Transl Sci"},{"key":"14982_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/OTT.S3863","volume":"2","author":"F Di Costanzo","year":"2009","unstructured":"Di Costanzo F, Gasperoni S, Rotella V, Di Costanzo F. Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer. Onco Targets Ther. 2009;2:179\u201388.","journal-title":"Onco Targets Ther"},{"issue":"3","key":"14982_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","volume":"21","author":"RH Jones","year":"2020","unstructured":"Jones RH, Casbard A, Carucci M, Cox C, Butler R, Alchami F, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2020;21(3):345\u201357.","journal-title":"Lancet Oncol"},{"issue":"20","key":"14982_CR33","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929\u201340.","journal-title":"N Engl J Med"},{"key":"14982_CR34","doi-asserted-by":"publisher","first-page":"vi80","DOI":"10.1093\/annonc\/mdz374.001","volume":"30","author":"H Iwata","year":"2019","unstructured":"Iwata H, Yamashita T, Inoue K, Takahashi M, Masuda N, Yamauchi T, et al. PS1-3 - Alpelisib (ALP)\u2009+\u2009fulvestrant (FUL) in patients from Japan with advanced breast cancer: subgroup analysis of SOLAR-1 trial. Ann Oncol. 2019;30(Suppl 6):vi80.","journal-title":"Ann Oncol"},{"issue":"7","key":"14982_CR35","doi-asserted-by":"publisher","first-page":"e488","DOI":"10.1093\/oncolo\/oyad024","volume":"28","author":"X Ge","year":"2023","unstructured":"Ge X, Behrendt CE, Yost SE, Patel N, Samoa R, Stewart D, et al. Predicting hyperglycemia among patients receiving alpelisib plus fulvestrant for metastatic breast cancer. Oncologist. 2023;28(7):e488\u201392.","journal-title":"Oncologist"},{"issue":"4 Suppl","key":"14982_CR36","first-page":"PD1","volume":"81","author":"P Schmid","year":"2021","unstructured":"Schmid P, Abraham J, Chan S, Brunt AM, Nemsadze G, Baird RD, et al. Abstract PD1-11: mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer. Cancer Res. 2021;81(4 Suppl):PD1-11.","journal-title":"Cancer Res"},{"issue":"1 Suppl","key":"14982_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101395","volume":"8","author":"P Neven","year":"2023","unstructured":"Neven P, Hamilton E, Pistilli B, Borges V, Campone M, Foukakis T, et al. 206P Capivasertib (C)\u2009+\u2009palbociclib (P) and fulvestrant (F) in patients (pts) with HR+\/HER2- advanced breast cancer (ABC): phase Ib data from CAPItello-292. ESMO Open. 2023;8(1 Suppl):101395.","journal-title":"ESMO Open"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14982-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T22:02:42Z","timestamp":1760479362000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14982-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14982"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14982-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with International Council for Harmonisation\/Good Clinical Practice, applicable regulatory requirements, and the sponsor policy on bioethics. The study was approved by the Medical Ethics Committee of Fudan University Shanghai Cancer Center on June 17, 2020 (approval no 2005217-11).All patients provided signed informed consent before admission to the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LZ and EF are employees of AstraZeneca. MC and CC are former employees of AstraZeneca and may have ownership, options, and\/or interests in AstraZeneca stock. XH, YD, XL, Y Mu, Y Meng, and YS declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1562"}}